You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 282 No. 15, October 20, 1999 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Editorial
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Citing articles on ISI (23)
 •Contact me when this article is cited
 Related Content
 •Related article
 •Similar articles in JAMA
 Topic Collections
 •Drug Therapy, Other
 •Conflict of Interest
 •Alert me on articles by topic

Conflict of Interest and Cost-effectiveness Analysis

Sheldon Krimsky, PhD

JAMA. 1999;282:1474-1475.

Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

More than 30 years ago, Bronowski, who spoke so poetically about the ethos of science, wrote that "the body of scientists is trained to avoid and organized to resist every form of persuasion but the fact."1 The values of science, he argued, are "inescapable conditions for its practice."1 But the practice of science, especially the biomedical sciences, has changed significantly since Bronowski made his observations. Increasingly, academic biomedicine has become commingled with corporate interests. Spurred by the burgeoning commercial opportunities of new discoveries such as those in genetics, the growth in academic-industry collaborations has created uneasiness among some observers who suspect that conditions beyond the pure facts of science can influence its outcome.

During the mid-1980s, several medical journals, including JAMA, adopted policies on conflicts of interest.2-3 According to 1 survey conducted in 1994-1995, nearly 50% of US medical journals with a circulation greater than 1000 . . . [Full Text of this Article]

Author Affiliation: Department of Urban and Environmental Policy, Tufts University, Medford, Mass.


RELATED ARTICLE

Evaluation of Conflict of Interest in Economic Analyses of New Drugs Used in Oncology
Mark Friedberg, Bernard Saffran, Tammy J. Stinson, Wendy Nelson, and Charles L. Bennett
JAMA. 1999;282(15):1453-1457.
ABSTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Transparency in Communication: An Examination of Communication Journals' Conflicts-of-Interest Policies
Soley and Feldner
Journal of Communication Inquiry 2006;30:209-228.
ABSTRACT  

Cost effectiveness of foldable multifocal intraocular lenses compared to foldable monofocal intraocular lenses for cataract surgery
Dolders et al.
Br. J. Ophthalmol. 2004;88:1163-1168.
ABSTRACT | FULL TEXT  

The Thought Style of Physicians: Strategies for Keeping up with Medical Knowledge
de Camargo
Social Studies of Science 2002;32:827-855.
ABSTRACT  

Editorial I: Conflicts of interest: are they a problem for anaesthesia journals? What should we do about them?
Sneyd
Br J Anaesth 2000;85:811-814.
FULL TEXT  

Problems With the Interpretation of Pharmacoeconomic Analyses: A Review of Submissions to the Australian Pharmaceutical Benefits Scheme
Hill et al.
JAMA 2000;283:2116-2121.
ABSTRACT | FULL TEXT  

Sources of Bias in the Economic Analysis of New Drugs
Gagnon et al.
JAMA 2000;283:1423-1424.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1999 American Medical Association. All Rights Reserved.